There’s good news for people with severe treatment-resistant depression: Esketamine is a groundbreaking therapy that can provide relief from major depression within hours.

Esketamine nasal spray is recommended for adults diagnosed with major depressive disorder (MDD) who did not respond to at least two antidepressants, and who currently have a major …

6 days ago · Objective: Intranasal esketamine has been approved as an adjunctive therapy for treatment-resistant major depressive disorder with acute suicidal ideation and behavior. The …

Jan 21, 2025 · SPRAVATO ® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression Following U.S. FDA Priority …

Sep 26, 2019 · For patients with intractable depression, a new esketamine clinic — among the first in the U.S. — can provide immediate relief.

6 days ago · Objective: Intranasal esketamine has been approved as an adjunctive therapy for treatment-resistant major depressive disorder with acute suicidal ideation and behavior. The …

Oct 4, 2023 · In this trial involving patients with treatment-resistant depression, esketamine nasal spray was superior to the comparator, extended-release quetiapine, a commonly used …

Objective: To review the pharmacology, pharmacokinetics, efficacy, safety, use requirements, and place in therapy of esketamine for treatment-resistant depression (TRD). Data Sources: A …

The overall findings demonstrated that treatment with intranasal esketamine in combination with a new oral antidepressant was more effective than placebo plus an oral antidepressant, and …

Intranasal esketamine has shown efficacy in reducing depressive symptoms in clinical trials, but the clinical meaningfulness of the treatment effect in the real-world population still needs to be …